Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toward Overcoming Treatment Failure in Rheumatoid Arthritis
Zhuqian Wang, Jie Huang, Duoli Xie, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Lindsay J. Marshall, Jarrod Bailey, Manuela Cassotta, et al.
Alternatives to Laboratory Animals (2023) Vol. 51, Iss. 2, pp. 102-135
Open Access | Times Cited: 63
Stigmasterol mitigates rheumatoid arthritis progression by decreasing Nrf2/NLRP3-mediated pyroptosis in chondrocyte
Ding Li, Huijun Lin, Zhidong Ma, et al.
Molecular Immunology (2025) Vol. 179, pp. 9-17
Closed Access | Times Cited: 2
Advancing Autoimmune Rheumatic Disease Treatment: CAR-T Cell Therapies - Evidence, Safety, and Future Directions
Ryunosuke Ohno, Akihiro Nakamura
Seminars in Arthritis and Rheumatism (2024) Vol. 67, pp. 152479-152479
Open Access | Times Cited: 13
METTL14 promotes fibroblast-like synoviocytes activation via the LASP1/SRC/AKT axis in rheumatoid arthritis
Xuan’an Li, Xuezheng Xu, Qi‐Lei Zhang, et al.
AJP Cell Physiology (2023) Vol. 324, Iss. 5, pp. C1089-C1100
Closed Access | Times Cited: 17
Clinical evidence construction of East Asian herbal medicine for inflammatory pain in rheumatoid arthritis based on integrative data mining approach
Hee-Geun Jo, Jihye Seo, Donghun Lee
Pharmacological Research (2022) Vol. 185, pp. 106460-106460
Closed Access | Times Cited: 22
Supramolecular Integration of Multifunctional Nanomaterial by Mannose-Decorated Azocalixarene with Ginsenoside Rb1 for Synergistic Therapy of Rheumatoid Arthritis
Shihui Li, Juanjuan Li, Yingying Zhao, et al.
ACS Nano (2023) Vol. 17, Iss. 24, pp. 25468-25482
Closed Access | Times Cited: 11
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE
Roy Fleischmann, Ricardo Blanco, Filip Van den Bosch, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 599-615
Open Access | Times Cited: 4
Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years
Jingyuan Li, Wei Li, Liping Zhuang
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study
Andrew J.K. Östör, Eugen Feist, Prodromos Sidiropoulos, et al.
Arthritis Research & Therapy (2025) Vol. 27, Iss. 1
Open Access
Unsupervised discovery of clinical disease signatures using probabilistic independence
Thomas A. Lasko, William W. Stead, John M. Still, et al.
Journal of Biomedical Informatics (2025), pp. 104837-104837
Open Access
Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial
Jia Wang, Sheng‐Xiao Zhang, Jia-Song Chang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Therapeutic potential of probiotics in gut microbial homeostasis and Rheumatoid arthritis
Dhivyadharshini Balasundaram, V.S. Veerasamy, Magdalin Sylvia Singarayar, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112501-112501
Closed Access | Times Cited: 3
Immune checkpoint molecules in prevention and development of asthma
Zahra Kanannejad, Saeede Soleimanian, Zahra Ghahramani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Radiotracers for Imaging of Inflammatory Biomarkers TSPO and COX-2 in the Brain and in the Periphery
Bright Chukwunwike Uzuegbunam, Christoph Rummel, Damiano Librizzi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 24, pp. 17419-17419
Open Access | Times Cited: 6
An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis
Jency R. Rajan, Stephen McDonald, Anthony J. Bjourson, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 12, pp. 1633-1633
Open Access | Times Cited: 5
A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™
Patrick L. Iversen, Nicholas Kipshidze, Nodar Kipshidze, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 4
Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
Zhe Yu, Ling Gao, Yinshan Zang, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 1
Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies
LILIANA BORDEAN, Monica Chiș, ANCA MARIA CIMPEAN, et al.
In Vivo (2023) Vol. 37, Iss. 5, pp. 2387-2401
Open Access | Times Cited: 3
Factors Influencing Adalimumab Treatment Response in Patients with Rheumatoid Arthritis: The Future of Clinical Expertise
Samer Imad Mohammed, Ali L. Jasim, Mohammed Jamal Yawuz, et al.
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2023) Vol. 5, pp. 192-204
Open Access | Times Cited: 2
Integrative medicine using East Asian herbal medicine for inflammatory pain in patients with rheumatoid arthritis: A protocol for systematic review and meta-analysis integrated with multiple data mining for core candidate discovery
Hee-Geun Jo, Jihye Seo, Eunhye Baek, et al.
Medicine (2023) Vol. 102, Iss. 23, pp. e33903-e33903
Open Access | Times Cited: 1
An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis
Jency R. Rajan, Stephen McDonald, Anthony J. Bjourson, et al.
(2023)
Open Access | Times Cited: 1
What benefit–risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment
Rieke Alten, Juan Carlos Nieto‐González, Peggy Jacques, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003311-e003311
Open Access
Stigmasterol mitigates rheumatoid arthritis progression by decreasing Nrf2/NLRP3-mediated pyroptosis in chondrocyte
Ding Li, Lianbo Xiao, Huijun Lin, et al.
Research Square (Research Square) (2024)
Closed Access
A study of the molecular mechanism of action of Jiawei Guizhishaoyaozhimu Decoction during rheumatoid arthritis therapy based on basic of network pharmacology and experimental verification
Yiji Cheng, Yue Ji, Kaidi Feng, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access
Elevated Serum Levels of YKL-40, YKL-39, and SI-CLP in Patients with Treatment Failure to DMARDs in Patients with Rheumatoid Arthritis
José David Tadeo Esparza-Díaz, Jorge Iván Gámez-Nava, Laura González-López, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1406-1406
Open Access
Page 1 - Next Page

Scroll to top